Gene signature helps identify risk of relapse in lung cancer patients
A new genetic signature identified by Spanish researchers may provide doctors with robust and objective information about which patients with early stage lung cancer are at low or high risk of relapse following surgery, investigators report at the 3rd European Lung Cancer Conference in Geneva. Their work also opens new avenues for immunotherapy for lung cancer.
Non-small cell lung cancer is a disease that is often not diagnosed until it has grown and spread throughout the body. Even those patients who are diagnosed early enough to undergo surgical removal of the tumor still have a discouraging 30% rate of relapse.
Researchers hope that identifying which patients have the greatest risk of relapse will allow doctors to focus other treatment strategies, in order to improve their chance of being cured after surgery.
A multidisciplinary team of researchers from Hospital Clinico San Carlos, Madrid, have found a 50-gene predictor that appears to be capable of doing just that. In a study of 84 patients with stage I and II non-small cell lung cancer, who had undergone surgery to remove their tumor, the gene signature accurately predicted which patients were at low risk of relapse.
The researchers analyzed genetic expression in the tumor mass using microarray technology. Following patients for six years, they were able to correlate gene expression patterns with the clinical course of disease, and the risk of relapse.
The Spanish research team's report at the meeting shows that the genes of the predictor were over-expressed in roughly one-third of patients, all of whom had a low risk of relapse. Further analysis showed that these genes were related to the activity of important immune system white blood cells, known as B lymphocytes.
"All of these genes overexpressed in the low-risk group are highly related to B lymphocyte activity," said Dr Florentino Hernando presenting the results at the meeting. "So, the B cell-mediated immune response seems to have a very important role."
The genetic profile identified by the researchers suggests that low-risk patients have an enhanced immune response against the tumor. "Thus, treatments that may interfere with this response such as post-surgical chemotherapy must be reconsidered for the low-risk subgroup," he says.
"One third of patients show an overexpression of an 'immune' genetic signature in their tumor specimens, that is associated with better prognosis," Dr Hernando said. "The fact that this B cell-dependent immune response was associated to the good outcome suggests we should investigate its therapeutic applications in the management of these patients after surgical resection."
Commenting on the study, which he was not involved in, Prof David Carbone from the Vanderbilt-Ingram Cancer Center, member of the IASLC Board, said: "The Spanish group studied tumors from 84 patients with completely resected stage I and II lung cancer for gene RNA expression profiles using 41,000 different probes. Since over half of these patients relapse and die from their cancer in spite of complete resection, there is a pressing need for both defining those patients at the greatest risk of relapse for trials of adjuvant therapy, but also potentially avoiding the toxicity of adjuvant therapy in patients with a low risk of relapse. This is a potentially extremely important classifier, which if independently validated, could be the basis of such a test. It is interesting that the majority of the genes in the classifier are either immune-derived or immunomodulatory, suggesting a potential molecular basis for this observation. It would be interesting to compare the results of this classifier to simple quantitation of lymphocytic infiltration into the resected tumors.
Provided by European Society for Medical Oncology
- New biomarker that predicts breast cancer relapse found May 16, 2011 | not rated yet | 0
- Identifying lung cancer gene markers shows promise in identifying patients needing chemo Dec 09, 2010 | not rated yet | 0
- Researchers find malignancy-risk gene signature for early-stage non-small cell lung cancer Jan 06, 2012 | not rated yet | 0
- New genetic techniques to combat lung cancer Apr 25, 2008 | not rated yet | 0
- Genetic pattern that predicts leukemia relapse discovered May 11, 2010 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
5 hours ago From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
22 hours ago I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...
Cancer 17 hours ago | not rated yet | 0
(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...
Cancer 17 hours ago | not rated yet | 0 |
A new review finds cancer survivors suffer a diverse and complex set of impairments, affecting virtually every organ system. Writing in CA: A Cancer Journal for Clinicians, Julie Silver, M.D., associate professor at Harvar ...
Cancer 22 hours ago | not rated yet | 0
(AP)—A California doctor has been sentenced to 14 years in federal prison for bilking her patients out of more than $1 million by promising that an herbal supplement could cure late-stage cancer and other diseases.
Cancer 22 hours ago | not rated yet | 0
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
Cancer May 17, 2013 | not rated yet | 0 |
Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.
6 hours ago | 5 / 5 (1) | 0
For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests
Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...
7 hours ago | not rated yet | 0 |
(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...
19 hours ago | 3.7 / 5 (3) | 0 |
The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...
18 hours ago | not rated yet | 0 |
In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...
16 hours ago | 3.7 / 5 (3) | 0 |